ARTICLE | Company News
ImmunoGen other research news
June 12, 1995 7:00 AM UTC
IMGN (Cambridge, Mass.) received a $750,000 Phase II SBIR from the National Cancer Institute to develop targeted immunoconjugate drugs for cancer. IMGN will use humanized monoclonal antibodies linked ...